热门资讯> 正文
enGene Holdings GAAP每股收益为2.29美元
2025-12-23 05:05
- enGene Holdings press release (ENGN): FY GAAP EPS of $2.29.
- Full Year Financial Results ended October 31, 2025Total operating expenses were $123.2 million for the full year ended October 31, 2025, compared to $62.3 million for 2024. Research and development expenses increased by $56.2 million, primarily driven by increased manufacturing, personnel and clinical costs related to our LEGEND trial and in preparation for our planned Biologics License Application submission in the second half of 2026.
More on enGene Holdings
- enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC - Slideshow
- enGene Holdings: Still A Buy After A Massive Surge
- enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript
- enGene announces proposed public offering
- Seeking Alpha’s Quant Rating on enGene Holdings
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。